Dr. Diefenbach is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
240 East 38th Street
19th Floor
New York, NY 10016Phone+1 212-731-5670Fax+1 212-731-5502- Is this information wrong?
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2008
Johns Hopkins UniversityResidency, Internal Medicine, 2001 - 2004
Perelman School of Medicine at the University of PennsylvaniaClass of 2001
Certifications & Licensure
NY State Medical License 2004 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma Start of enrollment: 2012 Aug 31
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
- Join now to see all
Publications & Presentations
PubMed
- KLRG1, Another Opportunity for a Breakthrough in MTCL.Gaurav Varma, Catherine S Diefenbach> ;Clinical Cancer Research. 2024 Apr 3
- Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.Lihua E Budde, Sarit Assouline, Laurie H Sehn, Stephen J Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, ...> ;Journal of Clinical Oncology. 2024 Mar 28
- 1 citationsPolatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase...Abrisqueta, P., González-Barca, E., Panizo, C., Pérez, J., Miall, F., Bastos-Oreiro, M., Triguero, A., Banerjee, L., McMillan, A., Hirata, J., de Guzman, J., Sharma, S...> ;The Lancet. Haematology. 2024 Feb 1
- Join now to see all
Journal Articles
- Ipilimumab, Nivolumab, and Brentuximab Vedotin Combination Therapies in Patients with Relapsed or Refractory Hodgkin Lymphoma: Phase 1 Results of an Open-Label, Multic...Catherine (Magid) Diefenbach, MD, The Lancet Haematology
- CART19 in Hodgkin Lymphoma: Are We Driving the Right Model?Catherine (Magid) Diefenbach, MD, Blood
Abstracts/Posters
- The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relap...Catherine Diefenbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analys...Catherine Diefenbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)Catherine Diefenbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicit...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a p...2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Press Mentions
Saving Lives and Making a Killing | Jerome GroopmanMay 4th, 2023- Unraveling When and How to Perform MRD Testing in Mantle Cell LymphomaNovember 23rd, 2022
- Programming the Immune System to Supercharge Cancer Cell TherapiesMarch 16th, 2022
- Join now to see all
Hospital Affiliations
NYU Langone HospitalsNew York, New York
NYC Health + Hospitals / South Brooklyn HealthBrooklyn, New York
NYC Health + Hospitals / BellevueNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
